Boston Scientific reported fourth-quarter revenues of $5.29 billion, surpassing the consensus estimate by $10 million and exceeding its own guidance range of $5.22 billion to $5.31 billion. Adjusted earnings per share came in at $0.80, above both the consensus forecast of $0.78 and the company’s internal guidance of $0.77–$0.79. On an organic basis, revenue growth reached 12.7%, reflecting broad-based strength across cardiovascular (up 16.1% organically to $3.48 billion), MedSurg (up 6.5% organically to $1.81 billion) and its faster-growing neuromodulation and endoscopy franchises.

Management issued full-year 2026 guidance calling for reported net sales growth of 10.5%–11.5% (10%–11% organically), implying revenues between $22.18 billion and $22.38 billion. This outlook fell slightly shy of analyst expectations, which centered around $22.37 billion, and pegged adjusted earnings per share at $3.43–$3.49 versus a consensus of $3.47. The cautious forecast for electrophysiology—expected to grow low-teens—and the reminder of ongoing AXIOS stent safety reviews contributed to a rapid, high-volume liquidation that erased several months of gains.

Despite beating on both sales and earnings, Boston Scientific shares plunged more than 17% on the day following the guidance announcement, marking the largest one-day percentage decline since 2018. However, many strategists describe this move as an overreaction given the company’s robust free cash flow projection of $4.2 billion for 2026 and a track record of 12 consecutive quarters of double-digit organic growth.

On February 5, Needham analyst Mike Matson raised his price target to $97, suggesting upside of over 28% from current levels. The upgrade was driven by confidence in Boston Scientific’s diversified portfolio—including the recently FDA-approved FARAPOINT Pulsed Field Ablation catheter and the SEISMIQ Intravascular Lithotripsy system—and the expectation that accelerating adoption of minimally invasive therapies will sustain mid-teens revenue growth beyond 2026.